Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01519076




Registration number
NCT01519076
Ethics application status
Date submitted
18/01/2012
Date registered
26/01/2012
Date last updated
10/12/2014

Titles & IDs
Public title
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
Scientific title
A Feasibility Study: A Safety Evaluation of the Use of Magnetic-guided Iron Particles Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)
Secondary ID [1] 0 0
PTI_CS001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ischemic Stroke 0 0
Condition category
Condition code
Stroke 0 0 0 0
Haemorrhagic
Stroke 0 0 0 0
Ischaemic

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)

Treatment: Devices: Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)
The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety: incidence and evaluation of any adverse effects associated with the investigational procedure compared with historical controls treated with tPA alone.
Timepoint [1] 0 0
90 days
Secondary outcome [1] 0 0
Brain Recanalization and perfusion
Timepoint [1] 0 0
24 hours

Eligibility
Key inclusion criteria
* Subject is between 18 and 80 years of age.
* Subject has moderate to large (NIHSS = 10 and =24) ischemic stroke
* Subject has an intracranial arterial occlusion of the middle cerebral artery (MCA), anterior cerebral artery (ACA), internal carotid artery (ICA), posterior cerebral artery (PCA) or distal basilar artery confirmed by CT or MR angiography.
* Subject is eligible for initiation of intravenous tPA within three hours of stroke onset, where time of stroke onset is defined as the last time the patient was witnessed to be at baseline.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject has known sensitivity to iron or PEG products.
* Subject has recently (within 30 days) received iron replacement therapy.
* Subject has known or suspect liver function abnormality.
* Subject has known or suspect severe renal impairment.
* Subject has a high-density lesion on baseline CT scan consistent with hemorrhage of any degree.
* Subject has a significant mass on baseline CT consistent with midline shift.
* Subject has a large (greater than one-third of the middle cerebral artery) regions of clear hypodensity on the baseline CT scan.
* Subject has evidence of intraparenchymal tumor on baseline CT scan.
* Subject experiences a seizure at the onset of stroke.
* Subject has known hemosiderosis or hemochromatosis.
* Subject has an implantable cardioverter defibrillator, pacemaker, neurostimulator or other device incompatible with MRI.
* Subject has a history of stroke within the last three months.
* Subject has a previous or existing intracranial hemorrhage, neoplasm, subarachnoid hemorrhage or arteriovenous malformation.
* Subject has experienced any active or recent (within 30 days) hemorrhage.
* Subject has systolic blood pressure > 185 mmHg or diastolic > 110 mmHg.
* Subject has presumed septic embolus or suspicion of bacterial endocarditis.
* Subject has presumed pericarditis including pericarditis after acute myocardial infarction.
* Subject is suspected to have an aortic dissection.
* Subject has recently (within 30 days) undergone surgery or biopsy of a parenchymal organ.
* Subject has recently (within 30 days) experienced trauma with internal injuries or ulcerative wounds.
* Subject has recently (within 90 days) experienced severe head trauma with loss of consciousness.
* Subject has known hereditary or acquired hemorrhage diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 1.7 or institutionally equivalent prothrombin time.
* Subject has a glucose level of < 50 mg/dl or >400 mg/dl, or a platelet count less than 100,000, or an Hct level less than 25.
* Subject has taken dabigatran within the last 48 hours or any new anticoagulant which cannot be monitored by traditional.
* Subject requires hemodialysis or peritoneal dialysis, or has a contraindication to angiogram.
* Subject has prolonged partial thromboplastin time (PTT) (in the case where heparin or a direct thrombin inhibitor has been administered within 48 hours).
* Subject has had a recent (within 7 days) lumbar puncture or arterial puncture at a non-compressible site.
* Subject has a pre-existing neurological or psychiatric disease that would confound evaluations.
* Subject is pregnant, nursing or intends to become pregnant during the trial period.
* Subject is currently enrolled in other potentially confounding research.
* Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2014
Sample size
Target
Accrual to date
Final
7
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Hunter New England - New Lambton
Recruitment hospital [2] 0 0
Eastern Health Services Box Hill Hospital - Box Hill
Recruitment postcode(s) [1] 0 0
- New Lambton
Recruitment postcode(s) [2] 0 0
- Box Hill

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pulse Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Christopher Bladin, MD
Address 0 0
Eastern Health Services Box Hill Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01519076